



Edwards

NEWS RELEASE

Edwards Lifesciences Advances Structural Heart Care Through Innovation and Purpose

2026-02-26

IRVINE, Calif.--(BUSINESS WIRE)-- At the close of Heart Month, Edwards Lifesciences (NYSE: EW) underscored its leadership in structural heart innovation, advancing care through deep expertise and strong partnerships so people with structural heart disease can live longer, healthier lives. As part of this commitment, Edwards announced the impact and renewed vision for Every Heartbeat Matters, its signature global health initiative, to help 2 million more patients facing barriers worldwide access lifesaving structural heart treatment by the end of 2030.

"For nearly 70 years, Edwards has led with a strong focus on improving the lives of patients with structural heart disease," said Bernard Zovighian, Edwards' CEO. "It starts with breakthrough innovation, layered with world class clinical expertise, sustained commitment and strong partnerships across the global healthcare ecosystem. Every advancement we make impacts a patient, a family and a community. Our purpose is to advance science and expand access so more people can benefit."

This commitment extends through the Edwards Lifesciences Foundation and Every Heartbeat Matters, which

increases access to diagnosis and treatment for underserved structural heart patients, particularly those in low- and middle-income countries and regions where care is limited and barriers may be substantial. Since 2014, Every Heartbeat Matters and its charitable partners have impacted more than 4 million underserved structural heart patients globally.

“Improving the lives of patients with structural heart disease is core to who we are,” Zovighian said. “Through Every Heartbeat Matters and our global partners, we are breaking down financial, systemic and geographic barriers so that underserved patients can get access to care that can change the trajectory of their lives. We innovate with purpose, we are powered by science and we remain centered on patients.”

More information on the Edwards Lifesciences Foundation and Every Heartbeat Matters is available at www.edwards.com/corporategiving or www.everyheartbeatmatters.org.

About Edwards Lifesciences

Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Discover more at www.edwards.com and follow us on LinkedIn, Facebook, Instagram and YouTube.

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements can sometimes be identified by the use of words such as “may,” “will,” “should,” “anticipate,” “believe,” “plan,” “project,” “estimate,” “forecast,” “potential,” “predict,” “early clinician feedback,” “expect,” “intend,” “guidance,” “outlook,” “optimistic,” “aspire,” “confident” or other forms of these words or similar expressions and include, but are not limited to, statements made by Mr. Zovighian, impact of Edwards’ therapies and innovation, including improving lives; access to care for underserved patients, changing the trajectory of their lives; and breaking down of barriers. No inferences or assumptions should be made from statements of past performance, efforts, or results which may not be indicative of future performance or results. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain, difficult to predict, and may be outside of the company’s control. The company’s forward-looking statements speak only as of the date on which they are made and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement. If the company does update or correct one or more of these statements, investors and others should not conclude that the company will make additional updates or corrections.

Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ

materially from that expressed or implied by the forward-looking statements. Factors that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements include risk and uncertainties associated with the risks detailed in the company's filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2025 and its other filings with the SEC. These filings, along with important safety information about our products, may be found at **edwards.com**.

Media Contact: Amy Meshulam, media@edwards.com

Investor Contact: Investor_Relations@edwards.com

Source: Edwards Lifesciences Corporation